50.6 F
New York
Friday, December 4, 2020

Gilead Sciences Inc. [NASDAQ: GILD] Shares Data Regarding HIV-1 Capsid Inhibitor Lenacapavir (GS-6207)

Must read

Ring [NYSEMKT: REI] Energy Started Drilling Operation In New Horizontal Well

Ring Energy declared that the company has started operations on its new well. The company told that in ten months, it finally initiated...

KKR [NYSE: KKR] Purchased Two Industrial Properties Of Worth $171Million

KKR & Co. Inc. announced that it purchased two properties in texas for distribution purposes. The industrial properties total an area of...

EchoStar [NASDAQ: SATS] Partners With JT And Brings A Single Terminal For Network Connectivity To Market

EchoStar Corp.  declared that it has collaborated with Jersey Telecom so that it can provide its clients in the United Kingdom and Europe...

Capstone [NASDAQ: CPST] Receives An 800Kw Microturbine Order From Costa

Capstone Turbine Corp. declared that it has acquired an order of 800KW microturbine from the Costa Group. The request was obtained by the...

Gilead Sciences Inc. [NASDAQ: GILD] today released data from an ongoing phase 1 study of Lenacapavir (GS-6207). The supporting data disclosed that a novel inhibitor of HIV-1 capsid function, lenacapavir (GS-6207), maintained treatment for at least six months following a single 900 mg dose.

The study disclosed that the Lenacapavir exhibited no negative effect. Lenacapavir is developed as a component of a long-acting regimen in combination with other antiretroviral agents. Lenacapavir damages the HIV capsid, a multimeric shell that help in viral replication throughout the viral life cycle.

The safety and effectiveness of Lenacapavir were studied in various clinical studies and have not yet been established. Lenacapavir has not gained approval from the US Food and Drug Administration yet and its safety and efficacy are not yet known.

Gilead’s shares traded up 0.38% and up +0.29 during the last trading session of Thursday. It has closed at $76.35. GILD has a gross margin of 79.40%, a profit margin of 21.80%, and an operating margin of 19.60%.

It has day low and day high range of 75.65-76.35, respectively. Gilead Sciences Inc has moved up 25.39% from its 52-weeks low and moved down -11.19% from its 52-weeks high. Its retrun on equity (ROE) is 22.60%, return on assets (ROA) is 8.10% and return on investment (ROI) is 9.50%.

More articles

Latest article

Vodafone [NASDAQ: VOD] and RingCentral signs a partnership to provide next-generation services

Vodafone signed a strategic alliance with Ring Central . The association will modify business connections and alliances. The enterprises have joined hands to...

Salesforce [NYSE: CRM] Enters A Deal To Acquire Slack

Salesforce engages in a contract to buy Slack at a worth of $27.7B. This purchase to build an operating system for the...

Xilinx [NASDAQ: XLNX] Announced That It Acquired Falcon Computing

Xilinx Inc. declared that it has purchased falcon Computing Solutions to make flexible computing more accessible and easily adapted by computer programmers. The...

Luokung Corp. [NASDAQ: LKCO] To Acquire EMG For RMB 836 Million

Luokung Technologies Corp. a location-based service company has agreed to buy EMG technologies for Ren Min Bi  836 million. The company will pay...

Nokia [NYSE: NOK] Extends Collaboration With AT&T to Deliver Seamless IoT Connectivity

Nokia Corp. declared that the company has extended its contract with AT&T . The collaboration among the companies can supply and provide an...

Wendy [NASDAQ: WEN] Strikes A Deal With Rebel Foods To Open 250 Cloud Kitchens.

Wendy’s Co. and Rebel foods have partnered to open about 250 cloud kitchens in India. These kitchens will only serve the customer with...

Tesla [NASDAQ: TSLA] Recalls 9537 SUV’s Because Of Manufacturing Issues

Tesla Inc. has released safety recall orders for more than 9500 of its vehicle in the United States. The vehicles include Model Xs...

Northrop [NYSE:NOC] awarded a deal of $4.8B for Global Hawk Aircraft

Northrop Gruman Corp. has been awarded a deal to perform development, transformation, retrofit, and sustenance activities for the Global Hawk Program. This deal...